RadNet (RDNT) just delivered a Q2 that caught investors’ attention, with revenue of $622.7 million, up 25% year on year, and both sales and earnings surpassing analyst expectations.
RadNet’s strong Q2 landed against a mixed trading backdrop, with the share price at $68.80 after declining 11.6% over the past month but gaining 10.6% over 90 days. The three year total shareholder return of roughly 140% points to powerful longer term momentum that recent weakness may be testing rather than reversing.
Scan the diagnostics theme beyond RadNet by comparing it with a curated 33 healthcare AI stocks that are riding the same demand for AI-driven medical imaging and testing.
After a sharp Q2 beat and a pullback that left RadNet down for the year, the key question now is straightforward: Has most of the upside already played out, or does valuation still leave meaningful room ahead?
Most Popular Narrative: 27.3% Undervalued
RadNet’s most widely followed narrative pegs fair value at $94.63, well above the recent $68.80 close, which puts the current pullback in a different light for anyone focused on long term cash generation.
The key requirement is that RadNet converts its heavy AI and digital health investment, including acquisitions and joint ventures with health systems, into sustainably higher margins and free cash flow despite ongoing labor and capital cost pressures.
The current valuation analysis suggests that the share price does not fully reflect the company’s record Q2 2026 revenue and adjusted EBITDA, growing advanced imaging contribution and rapidly scaling DeepHealth ARR, which this narrative views as consistent with RadNet being undervalued and the stock setup being favorable.
See why 8 investors see RadNet as 27% undervalued.
Result: Fair Value of $94.63 (UNDERVALUED)
Still, RadNet’s narrative can break if heavy AI and digital health spending keeps Digital Health EBITDA under pressure, or if new imaging capacity ends up underused.
Find out about the key risks to this RadNet narrative.
Next Steps
Mixed signals on RadNet so far, or a setup you want to test for yourself before sentiment swings again. Take a few minutes to weigh both sides by reviewing 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond RadNet?
Do not stop with RadNet. Broaden your watchlist using focused stock ideas that line up with the kind of risk and return profile you actually want.
- Target quality at a discount by scanning for companies that combine strong fundamentals with appealing valuations through a carefully filtered 33 high quality undervalued stocks.
- Prioritise resilience by zeroing in on businesses with sturdy finances and dependable balance sheets using a tailored list of solid balance sheet and fundamentals (25 results).
- Hunt for underfollowed opportunities by reviewing a curated 20 high quality undiscovered gems before everyone else pays attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com